Low‐dose famotidine and ranitidine as single post‐prandial doses: a three‐period placebo‐controlled comparative trial

Reilly, T G; Singh, Sukhdev; Cottrell, Jeremy J.; Mann, S. G.; Stauffer, Laura; Walt, R P

doi:10.1046/j.1365-2036.1996.50192000.x

Cited by 13 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As almost all studies regarding tolerance have involved subjects receiving long‐term ranitidine, information concerning this phenomenon with other H2RA is lacking. Famotidine has been reported to show a stronger and longer‐lasting acid‐suppressing effect than ranitidine and is the most potent H2RA currently used for clinical purposes 14–17 . Conflicting results have been reported concerning tolerance during famotidine administration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection

Komazawa

Adachi

Mihara

et al. 2003

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…There are very few clinically available data concerning tolerance to other H2RA. Famotidine is a more recently developed H2RA that is reported to have stronger acid‐suppressing activity than ranitidine 14–17 . There have been conflicting results concerning the development of tolerance to famotidine treatment 18 .…”

Section: Introductionmentioning

confidence: 99%

Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection

Komazawa

Adachi

Mihara

et al. 2003

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…This is at variance with the Reilly study which reported that famotidine 10 mg was superior to ranitidine 75 mg liquid. 7 This discordance could be attributed to methodological differences as the Reilly study was performed by automated pH-metry. Despite studies which suggest pharmacodynamic equivalence, it is more likely that the superiority of the famotidine 10 mg tablet was due to the decreased bioavailability of the ranitidine 75 mg liquid.…”

Section: Discussionmentioning

confidence: 99%

Nocturnal intragastric acidity after over‐the‐counter doses of famotidine, ranitidine or placebo

Grimley

Cottrell

Mann

et al. 1997

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

Aim: To compare the inhibitory effects of over‐the‐counter doses of famotidine or ranitidine on nocturnal intragastric acidity in a placebo‐controlled study. Methods: Twelve‐hour intragastric acidity was measured simultaneously in 24 healthy subjects who ate a standard meal at 18.30 h and were dosed (at 19.30 h) with either famotidine 10 mg, ranitidine 75 mg or placebo in a balanced three‐period crossover design. Five‐millilitre aliquots of gastric juice were aspirated half‐hourly 0–3 h post‐dose, and then hourly until the end of the study. pH was measured with a glass electrode. Integrated pH (area under the curve (AUC) of the pH–time curve) was calculated for the intervals 0–12 h and 9–12 h post‐dose. Statistical analysis was by ANOVA. Results: In the 0–12 h post‐dose period, when the 24 subjects were dosed with placebo, mean AUC was 2.12, dosed increasing by 75% to 3.70 with famotidine (P < 0.001) and by 81% to 3.83 with ranitidine (P < 0.001). In the 9–12 h post‐dose period, when the subjects were dosed with placebo, mean AUC was 2.13 increasing by 91% to 4.07 with famotidine (P < 0.001) and by 79% to 3.82 with ranitidine (P < 0.001). There was no significant difference between the pH‐raising effects of famotidine and ranitidine in both periods. Conclusions: Famotidine and ranitidine in over‐the‐counter doses have a similar, sustained, effect on post‐prandial nocturnal intragastric acidity in healthy subjects lasting up to 12 h after oral dosing.

show abstract

“…Over-the-counter H2RAs doses (ranitidine 75 mg, famotidine 10 mg), are less than those listed in the prescription product insert, however, at these doses they are effective in reducing overnight gastric acidity for 12 h [61], as well as blunting the food-stimulated gastric response [62,63]. They are also effective in the treatment of symptomatic GERD [47].…”

Section: Drugs Modulating Gastric Acidmentioning

confidence: 99%

Acid peptic diseases: pharmacological approach to treatment

Mejia

Kraft

2009

Expert Review of Clinical Pharmacology

102

View full text Add to dashboard Cite

Acid peptic disorders are the result of distinctive, but overlapping pathogenic mechanisms leading to either excessive acid secretion or diminished mucosal defense. They are common entities present in daily clinical practice that, owing to their chronicity, represent a significant cost to healthcare. Key elements in the success of controlling these entities have been the development of potent and safe drugs based on physiological targets. The histamine-2 receptor antagonists revolutionized the treatment of acid peptic disorders owing to their safety and efficacy profile. The proton-pump inhibitors (PPIs) represent a further therapeutic advance due to more potent inhibition of acid secretion. Ample data from clinical trials and observational experience have confirmed the utility of these agents in the treatment of acid peptic diseases, with differential efficacy and safety characteristics between and within drug classes. Paradigms in their speed and duration of action have underscored the need for new chemical entities that, from a single dose, would provide reliable duration of acid control, particularly at night. Moreover, PPIs reduce, but do not eliminate, the risk of ulcers in patients taking NSAIDs, reflecting untargeted physiopathologic pathways and a breach in the ability to sustain an intragastric pH of more than 4. This review provides an assessment of the current understanding of the physiology of acid production, a discussion of medications targeting gastric acid production and a review of efficacy in specific acid peptic diseases, as well as current challenges and future directions in the treatment of acid-mediated diseases.

show abstract

Low‐dose famotidine and ranitidine as single post‐prandial doses: a three‐period placebo‐controlled comparative trial

Abstract: We conclude that both famotidine 10 mg and ranitidine 75 mg significantly raise intragastric pH when given as single post-prandial doses. Famotidine 10 mg may have a greater effect than ranitidine elixir 75 mg over the 5-9-h period after dosing.

Cited by 13 publications

References 0 publications

Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection

Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection

Nocturnal intragastric acidity after over‐the‐counter doses of famotidine, ranitidine or placebo

Acid peptic diseases: pharmacological approach to treatment

Contact Info

Product

Resources

About